BC Consulting Group is a wholly owned subsidiary of ArrestedComputing and was formed in 2006 to provide small to medium-sized corporations with advice in the protection and commercialization of their Intellectual Property.

The content of this presentation is solely for the consumption of EntreMed employees.

Improper copying, viewing, or distribution of any proprietary material contained herein may subject you to criminal prosecution.

If you believe you have received this document in error, you should destroy it immediately.

Neither ArrestedComputing nor BC Consulting make any claims to the validity of any of the information contained herein. Actual results could differ materially from those currently anticipated due to a number of factors as statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties.

As always, you should carefully consider investment objectives, and all the risks, charges, and expenses associated with the recommendations before taking any action.

Presentation Overview

- Corporate Situational Breakdown
- Account of Intellectual Property Holdings
- Intellectual Property Utilization Analysis
- Recommendations

BC Consulting

Corporate Situational Breakdown

- Corporate Profile / Goals
- Finances
- Competition
- Risk Factors
- Products

BC Consulting

3

EntreMed, Inc. is a clinical-stage pharmaceutical company focused on developing next generation multi-mechanism oncology and anti-inflammatory drugs that target disease cells directly and the blood vessels that nourish them.

Angiogenesis is the physiological process involving the growth of new blood vessels from pre-existing vessels. Though there has been some debate over this, vasculogenesis is the term used for spontaneous blood-vessel formation, and intussusception is the term for new blood vessel formation by splitting of existing ones.

Angiogenesis is a normal process in growth and development, as well as in wound healing. However, this is also a fundamental step in the transition of tumors from a dormant state to a malignant state.

EntreMed's plan is to pursue many product candidates simultaneously. Corporate documents indicate the company's intention to aggressively pursue co-development alliances, funded research and licensing opportunities, as well as partnerships with pharmaceutical and biotechnology companies.



Since December 2004, EntreMed raised nearly $55 million through the sale of common stock to institutional investors and through the exercise of warrants held by Celgene Corporation. The company believes that the proceeds from these transactions, together with its cash, short-term investments and projected cash inflows, will support current and planned operations well into 2007.

EntreMed raised and addition 30M in gross proceeds through a private placement of common stock and warrants to institutional biotech investors



Competition in the pharmaceutical, biotechnology and biopharmaceutical industries is intense and based significantly on

- The availability of patent and other protection
- The ability and length of time required to obtain governmental approval
- Manufacturing & Marketing
- Ability to commercialize products in a timely fashion

Risk Factors

- **Development of Products is at an Early Stage and is Uncertain**
  - results of research and development activities
  - progress of preclinical studies or clinical trials
  - changes in or terminations of our relationships with strategic partners
  - competitive and technological advances
  - marketing and sales capabilities
  - manufacturing
  - the regulatory approval process

BC Consulting



Panzem, 2-methoxyestradiol or 2ME2, is EntreMed's lead clinical candidate. The 2ME2 mechanisms that are particularly relevant to the treatment of cancer involve inhibiting endothelial cell growth (antiangiogenic activity) and killing tumor cells directly (pro-apoptotic activity). Panzem was developed internally by EntreMed, and the Company owns exclusive rights to it.

MKC-1 is an orally-active, small molecule, cell cycle inhibitor with a unique mechanism of action. Specifically, MKC-1 arrests cellular mitosis by inhibiting a novel intracellular target important in cellular trafficking that has been shown to be involved in cell division. MKC-1 was acquired from in January 2006 when the company acquired Miikana Therapeutics, Inc., a clinical-stage biopharmaceutical company with research laboratories in Toronto, Canada.

In 1995, EntreMed signed a Research Collaboration and License Agreement with Bristol-Myers Squibb Company which through fiscal year 1998, provided EntreMed with $28.5 million. In 1999, EntreMed and Bristol-Myers Squibb jointly announced a modified Research and Development agreement allowing Entremed to re-assume development lead for the angiostatin protein.

One of EntreMed's strongest and most successful collaborations is with the National Cancer Institute. In September 1998, the National Cancer Institute, recognizing antiangiogenic cancer therapeutics as a promising strategy in the war on cancer, signed a Cooperative Research and Development Agreement (CRADA) with EntreMed to assist with clinical trials of Endostatin protein.

Account of Intellectual Property Holdings

- Registered Property
  - 19 patents
  - 3 trademarks

BC Consulting



Angiostatin is a human protein. It is a natural angiogenesis inhibitor (i.e., it blocks the growth of new blood vessels), and it is currently underlying clinical trials for its use in anticancer therapy.

EntreMed's patent holdings can be classified into a few sub areas

Production Methods
6723536 Method of producing and purifying angiostatin
6090617 Flow electroporation chamber with electrodes having a crystalline metal nitride coating
6074605 Flow electroporation chamber and method
5720921 Flow electroporation chamber and method

Methods for inhibiting cell proliferation
6805865 Compositions and methods for treating cancer and hyperproliferative disorders
6734163 Compositions and methods for inhibiting cellular proliferation
5981471 Compositions and methods for inhibiting cellular proliferation
5919459 Compositions and methods for treating cancer and hyperproliferative disorders
5814666 Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
5605885 Method for Stimulating the Immune System

Methods for treating angiogenic disease
6593291 Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
6544947 Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
6518298 Methods and compositions for inhibition of angiogenesis with EM-138
6413513 Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
6201104 Angiogenesis--inhibiting protein binding peptides and proteins and methods of use

Other treatment methods
6605622 Use of anti-estrogenic compounds as anti-fungal agents
6239123 Use of estrogenic compounds as anti-fungal agents
6224902 Vaccines against sterols
5753260 Vaccines against sterols

Trademarks

- “EntreMed”
- “The Angiogenesis Company”
- “Panzem”
- entremed.com (registered domain)

BC Consulting

Intellectual Property Utilization Analysis

- IP Risk Factors
  - failure to obtain additional patents
  - challenge, invalidation, or circumvention of patents already issued
  - failure of the rights granted under patents to provide sufficient protection
  - independent development of similar products by third parties
  - ability of third parties to design around patents

BC Consulting

IP Utilization

- EntreMed's Current Practice
  - Register patents for drugs and processes
  - Register TM names for drugs as they approach market readiness
  - TM various slogans

BC Consulting



Active:

Panzem: Production methods for Angiostatin, methods for treating angiogenic disease

MKC-1: Methods for inhibiting cell proliferation

Others: Methods for treating angiogenic disease

Inactive:

EntreMed has 5 patents in areas outside the main focus of the company. The areas of the patents include anti-fungal compounds and vaccines against sterols. We can explore methods of earning revenue from this unused intellectual property. EntreMed can either license or sell the rights to their patents to companies that specialize in the anti-fugnal medicines and vaccines against sterols. We also recommend that a search is performed to see if any companies are currently infringing the intellectual property rights of EntreMed and to pursue the appropriate legal actions against the infringers.

Sterols, or **steroid alcohols** are a subgroup of steroids. Sterols are important for the physiology of eukaryotic organisms. They form part of the cellular membrane where they modulate their fluidity and function and participate as secondary messengers in developmental signaling.

Different organisms utilize different sterols. The most important ones are cholesterol, phytosterols, and some steroid hormones in animals.



Selected abandoned trademarks

WE'RE NOT MAKING BETTER BLOOD, WE'RE MAKING BLOOD BETTER

DOING WELL BY DOING GOOD

PHOSAIC

ENTREVEST

VASCULOSTATIN

APOMIDE

…

Recommendations

- IP Protection Under Joint Ventures
- Partnerships for Manufacture and Marketing
- Reevaluation of Trademark Practices
- Licensing Unused IP
- Registering the EntreMed Logo
- Acquiring Additional Domains
- Angiogen

BC Consulting

Example:

Elan Corporation, plc (NYSE: ELN) and EntreMed, Inc. (NASDAQ: ENMD) today announced that they have entered into a License Agreement in which EntreMed has been granted rights to utilize Elan's proprietary NanoCrystal Technology to develop the oncology product candidate, Panzem ® NCD (2ME2 or 2-methoxyestradiol). Under the terms of the License Agreement, Elan is eligible to receive payments upon the achievement of certain clinical, manufacturing, and regulatory milestones. Additionally, Elan will receive royalty payments based on sales of Panzem ® NCD. (Source: biotechindustryblog.com 1/10/06)

Examples:

Bayer and Schering-Plough form partnership: Bayer said yesterday [September 14, 2004] that it had entered a partnership with Schering-Plough for marketing and distribution of Bayer's primary care pharmaceuticals, including the impotence drug Levitra in the United States and Puerto Rico. The deal will reduce Bayer's health care costs in the United States by 75 percent, affecting 1,800 jobs that will be cut or transferred to Schering-Plough, based in Kenilworth, N.J. Bayer, based in Leverkusen, Germany, will focus its United States health care business on profitable specialty drugs, biotechnology products and will start an oncology business unit with headquarters in West Haven, Conn. Petra Kappl (Source: New York Times Online Archive 9/14/04)

Partnership between Merck and Schering-Plough. Sales for Vytorin, a cholesterol-treating combination produced by Merck and Schering-Plough, have grown since its market debut last summer, but the drug's real test lies ahead, analysts say. Vytorin contains Zetia, a drug produced by Schering-Plough that inhibits absorption of cholesterol into the liver and intestine, and Zocor, the Merck blockbuster that cuts cholesterol. (Source: CNN Money 6/20/2005)

Reevaluation of Trademark Practices

- Get out of business of inventing and trade marking drug names
- Get out of Slogan Business
  - Most of this property ends up unused
  - Prospective partners will be much better equipped to handle this

BC Consulting



Cholesterol:

Pfizer (Lipitor)

AstraZeneca Pharm. (Crestor)

Merck & Schering Plough Partnership (Vytorin)

Anti-fungal:

Pfizer (fluconazole, Eraxis)

Procter & Gamble (pyrithione zinc)

Registering the EntreMed logo

BC Consulting

Acquiring Additional Domains

- entremed.net
- panzem.com
- entermed.com

BC Consulting



Angiogen’s patent #6576609; Methods & Compositions for Generating Angiostatin

EntreMed’s patent #6723536; Method of Producing and Purifying Angiostatin

Angiogen has one main patent #6576609 that covers methods and composition for generating angiostatin. This production method of angiostatin patented by Angiogen could infringe upon EntreMed’s patent #6723536. We would suggest a further investigation of the similarities between the processes because the end result product is angiostatin in both patents.

We noted earlier that the trademark “The Angiogenesis Company” has fallen into disuse. We recommend that EntreMed consider either attempting to defend this trademark against possible infringement by Angiogen (should the EntreMed marketing department wish to resurrect the mark) or otherwise consider selling this mark to the Angiogen rather than loose it at no benefit. This trademark of “The Angiogenesis Company” could come into play during negotiations with Angiogen about the possible patent infringement.

Then it could be decided whether to license, create a joint partnership, or pursue litigation against Angiogen with respect to patent infringement. EntreMed has been in the business of producing oncology drugs that target disease cells directly and was founded 4 years earlier. In addition, EntreMed is further along in clinical trials with the FDA for their angiogenesis drug Panzem than Angiogen who is a Phase I trial. Finally, since EntreMed is a publicly traded company and Angiogen is still a privately owned, there is much more transparency into EntreMed’s business and IP usage.

Final Remarks

- EntreMed is a small company totally dependant on intellectual property
- Only if it is able to successfully secure and commercialize it's IP, will EntreMed ever see profits

BC Consulting

Questions

BC Consulting

if you build it, we will come